1. The Lethal Clone in Prostate Cancer: Redefining the Index
Christopher E. Barbieri, Francesca Demichelis, Mark A. Rubin 
European Urology 
Volume 66, Issue 3, Pages (September 2014)
DOI: /j.eururo
Copyright © 2013 European Association of Urology Terms and Conditions

2. Fig. 1
Speckle-type POZ protein (SPOP), phosphatase and tensin homolog (PTEN), and tumor protein 53 (TP53) abnormalities across the spectrum of early and advanced prostate cancer. SPOP mutations occur in 10–15% of prostate cancer, with relatively stable prevalence across stages of disease. Mutations and deletions in PTEN and TP53 increase in frequency with advanced disease (but do not always occur together). Co-occurrence of SPOP mutations and PTEN and TP53 lesions are uncommon in early prostate cancer, but begin to overlap with advanced disease.
European Urology  , DOI: ( /j.eururo )
Copyright © 2013 European Association of Urology Terms and Conditions